Form 4: Crinetics CFO Sells Shares for Tax Obligations
Insider Transaction Report
Crinetics Pharmaceuticals' CFO, Tobin Schilke, sold 6,713 shares of common stock at an average price of $39.67 to cover tax withholding obligations related to RSU vesting.
Summary
- Tobin Schilke, Chief Financial Officer of Crinetics Pharmaceuticals, Inc. (CRNX), reported a transaction on March 3, 2026.
- The transaction involved the disposition of 6,713 shares of common stock.
- The shares were sold at a volume weighted average sales price of $39.67 per share, with a price range of $39.67 to $39.74.
- The sale was executed to cover the reporting person's tax withholding obligation upon the vesting of Restricted Stock Units (RSUs) that were granted on March 10, 2025.
- This disposition was made pursuant to a Rule 10b5-1 trading plan adopted by Tobin Schilke.
- Following this transaction, Tobin Schilke directly beneficially owns 78,121 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event. It is a routine, non-discretionary sale by an insider to cover tax liabilities associated with equity compensation, which is a common practice and does not reflect a change in sentiment towards the company's future.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.
Industry Context
StockSavvy.ai notes that sales of shares by executives to cover tax withholding obligations upon RSU vesting are a common and routine occurrence in the industry. These transactions are typically pre-planned under Rule 10b5-1 plans and do not usually indicate a change in management's confidence in the company's prospects.
Stakeholder Impact
- Shareholders: Minimal direct impact as this is a routine, pre-planned transaction for tax purposes and not a discretionary sale indicating a change in insider sentiment.
- Employees: No direct impact mentioned.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Date Restricted Stock Units (RSUs) were granted to the Reporting Person. |
| 03/03/2026 | Date of transaction where common stock was sold to cover tax withholding obligations. |
| 03/04/2026 | Date the Form 4 was signed by Tobin Schilke. |
Keywords
Crinetics Pharmaceuticals, CRNX, Tobin Schilke, CFO, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Rule 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.